Scabies

Summary

Scabies (MONDO:0004525) is a disease and 43 clinical trials. Top therapeutic interventions include permethrin, ivermectin, and moxidectin. A subtype of mite infestation — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 43

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	scabies
Mondo ID	MONDO:0004525
MeSH	D012532
DOID	DOID:8295
ICD-10-CM	B86
ICD-11	876005123
NCIT	C34998
SNOMED CT	128869009
UMLS	C0036262
MedGen	48566
Is cancer (heuristic)	no

Also known as: Sarcoptes scabiei caused disease or disorder · Sarcoptes scabiei disease or disorder · Sarcoptes scabiei infectious disease · sarcoptic itch

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › parasitic skin disorder › parasitic ectoparasitic infectious disease › mite infestation › scabies

Related subtypes (1): trombiculiasis

Subtypes (1): Norwegian scabies

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Crotamiton	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 43.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	14
Not specified	11
PHASE2	8
PHASE4	5
PHASE1	3
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07145736	PHASE4	RECRUITING	Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
NCT02775617	PHASE4	COMPLETED	Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
NCT04205669	PHASE4	COMPLETED	Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon
NCT05310734	PHASE4	UNKNOWN	PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies
NCT05819983	PHASE4	COMPLETED	Ivermectin/ Permethrin for Scabies
NCT06380452	PHASE3	NOT_YET_RECRUITING	Therapy for Scabies With Two Differently Concentrated Permethrin Creams
NCT07159373	PHASE3	NOT_YET_RECRUITING	Better Options for Lymphatic Filariasis Treatment
NCT02407782	PHASE3	COMPLETED	Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children and Adults
NCT02485704	PHASE3	COMPLETED	Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
NCT02485717	PHASE3	COMPLETED	Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
NCT02572986	PHASE3	COMPLETED	A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies
NCT02978508	PHASE3	COMPLETED	Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.
NCT03178942	PHASE3	COMPLETED	Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% in the Treatment of Scabies
NCT03236168	PHASE3	COMPLETED	Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands
NCT03676140	PHASE3	COMPLETED	Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
NCT03973775	PHASE3	COMPLETED	A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies
NCT04814511	PHASE3	UNKNOWN	Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin)
NCT04844905	PHASE3	UNKNOWN	Adjunctive Ivermectin Mass Drug Administration for Malaria Control
NCT06396507	PHASE3	COMPLETED	Sulfur vs. Different Regimes of Permethrin for Scabies
NCT05500326	PHASE2	ACTIVE_NOT_RECRUITING	Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)
NCT06896929	PHASE2	NOT_YET_RECRUITING	Comparison of Permethrin and Ivermectin in Children Greater Than 6 Yrs Age for Treatment of Scabies
NCT00262418	PHASE2	COMPLETED	Comparison of the Efficacy and Safety of Ivermectin to Permethrin
NCT02094716	PHASE2	COMPLETED	A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies
NCT03905265	PHASE2	COMPLETED	Dose-finding Study of Moxidectin for Treatment of Scabies
NCT04332068	PHASE2	COMPLETED	Ivermectin Safety in Small Children
NCT05875441	PHASE2	COMPLETED	Efficacy and Safety Study of Moxidectin in Adults With Scabies
NCT06404333	PHASE2	COMPLETED	Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15)
NCT05362513	PHASE1	COMPLETED	Comparative Study Between Topical Permethrin 5% and Oral Ivermectin for the Treatment of Scabies
NCT05862701	PHASE1	COMPLETED	Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies
NCT06918665	PHASE1	SUSPENDED	HEALTH Trial - Healthy Adult Evaluation of Ivermectin Bioequivalence: Infant Versus Standard Formulation
NCT06546579	EARLY_PHASE1	RECRUITING	Sensitivity of Self-collected Skin Sampling for Scabies: a Pilot Study
NCT07247630	EARLY_PHASE1	NOT_YET_RECRUITING	Comparison of Permethrin-Based Treatment Strategies Against Scabies in Infants and Young Children
NCT07506967	Not specified	NOT_YET_RECRUITING	Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
NCT00604084	Not specified	COMPLETED	Veron Scabies Education and Eradication Program
NCT00884728	Not specified	COMPLETED	Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia’s Northern Territory
NCT02254564	Not specified	COMPLETED	PCR (Polymerase Chain Reaction) Assay for Diagnosis of Sarcoptes Scabiei
NCT03177993	Not specified	COMPLETED	Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji
NCT04931680	Not specified	UNKNOWN	Risk Factors for Treatment Failure of Scabies in Autochthonous Populations of French Guiana (GUYAGALE)
NCT05025696	Not specified	COMPLETED	Efficacy and Side Effects of Blacksoap® as Adjuvant Therapy of Scabies
NCT05117528	Not specified	COMPLETED	Streptococcus Pyogenes Carriage Acquisition and Transmission Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PERMETHRIN	4	13
IVERMECTIN	4	7
MOXIDECTIN	4	3
SULFUR	4	2
ALBENDAZOLE	4	1
AZITHROMYCIN	4	1
BENZYL BENZOATE	4	1
DIETHYLCARBAMAZINE	4	1
SPINOSAD	4	1
CHEMBL263291	0	12
CHEMBL4082099	0	7
CHEMBL4788951	0	7
CHEMBL4782609	0	3
CHEMBL5280985	0	3
CHEMBL4299381	0	1
CHEMBL2040681	0	1
CHEMBL48977	0	1